In its latest weekly influenza report, Hong Kong's Centre for Health Protection (CHP) today confirmed 29 new H7N9 avian flu cases in mainland China, the most since late February. There have now been 616 cases of H7N9 reported in China since October of last year, in what is the country's fifth wave of the disease, the CHP said.
New study estimates about 2,100 travelers return with the disease each year and almost 1,500 need hospitalization.
Meta-analysis shows a 21% higher antibiotic prescribing rate in patients who tested negative for malaria.
Two studies suggest DSM265 is a medium-potency, slowly eliminated, well-tolerated antimalarial.
Neuraminidase inhibitors, the antiviral drugs given to fight and prevent influenza, pose no safety risks to fetuses or newborns, according to a new study published today in BMJ. This is the largest study on antiviral use and safety in pregnancy conducted to date.
The first known case of malaria resistant to the essential drug artemisinin was reported yesterday in the New England Journal of Medicine.
Five more babies have been born in the United States with Zika-related birth defects, according to updated data from the Centers for Disease Control and Prevention (CDC). There are now 43 babies in the country with documented defects from the mosquito-borne illness.
China reported two more H7N9 avian influenza cases, including the season's second case detected in Beijing, according to official sources and state media.
UK researchers report that a frontline drug combo failed in 4 patients.
The Los Angeles County Department of Public Health (LAC DPH) reported yesterday that a bacterial isolate harboring the MCR-1 gene, which confers resistance to the last-resort antibiotic colistin, has been identified in a patient with an Escherichia coli infection.
